ArticleClinical and experimental medicine2026
Long noncoding RNA SRRM2-AS1 mediates coronary artery damage in Kawasaki disease by promoting endothelial-to-mesenchymal transition.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Kawasaki disease (KD) is the leading cause of acquired heart disease in children, though its etiology and underlying mechanisms remain elusive. Emerging evidence indicates that long noncoding RNAs (lncRNAs) regulate endothelial-to-mesenchymal transition (EndMT), a cellular process implicated in vascular pathology. However, the specific involvement of lncRNAs in KD-associated coronary artery damage via EndMT remains undefined. Here, we show that the lncRNA SRRM2-AS1 is markedly elevated in the serum of children with KD and is internalized by coronary artery endothelial cells. Overexpression of SRRM2-AS1 in human coronary artery endothelial cells (HCAECs) increased cell migration and induced EndMT, as confirmed by elevated mesenchymal marker expression and morphological changes. Mechanistically, bioinformatics analysis, dual-luciferase reporter assays, and gene expression profiling revealed SRRM2 as a direct target of SRRM2-AS1. Our findings suggest that SRRM2 promotes EndMT through ubiquitin C (UBC) and the PI3K/Akt/GSK-3β/β-catenin signaling pathway. In a mouse model of KD, recombinant AAV9-mediated SRRM2-AS1 overexpression intensified coronary artery inflammation and increased vimentin expression, further supporting its role in EndMT. Collectively, these results demonstrate that SRRM2-AS1 drives EndMT in KD via the SRRM2/UBC/PI3K/Akt/GSK-3β/β-catenin axis, thereby contributing to coronary artery damage. Consequently, SRRM2-AS1 emerges as a promising therapeutic target for KD-associated vasculopathy, offering potential avenues to mitigate cardiovascular complications in affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.